New drug itepekimab tested for Long-Term safety in nasal polyp patients
NCT ID NCT07424144
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 study tests the long-term safety of itepekimab, an injected drug, in 380 adults with chronic sinusitis and nasal polyps that are hard to control. Participants previously completed a one-year study on itepekimab. The trial lasts up to 72 weeks and also checks if the drug continues to work over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
itepekimab
What this could lead to
If successful, this could confirm itepekimab as a safe long-term treatment option for people with hard-to-control nasal polyps and sinusitis.
What could go wrong
This is an extension study focused on safety, not a new efficacy trial. It may not show major new benefits, and side effects could still emerge over longer use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allergy, Asthma and Clinical Research- Site Number : 8402002
Oklahoma City, Oklahoma, 73120, United States
-
Investigational Site Number : 0362001
Spearwood, Western Australia, 6163, Australia
-
Investigational Site Number : 1241001
Québec, Quebec, G1V 4G5, Canada
-
Investigational Site Number : 1242003
Québec, Quebec, G1V 4W2, Canada
-
Investigational Site Number : 1242012
Québec, Quebec, G2J 0C4, Canada
-
Investigational Site Number : 1521001
Santiago, Reg Metropolitana de Santiago, 8207257, Chile
-
Investigational Site Number : 1521002
Santiago, Reg Metropolitana de Santiago, 7500692, Chile
-
Investigational Site Number : 1521003
Talca, Maule Region, 3465584, Chile
-
Investigational Site Number : 1522001
Concepción, Biobio, 4070094, Chile
-
Investigational Site Number : 1522003
Santiago, Reg Metropolitana de Santiago, 7500505, Chile
-
Investigational Site Number : 1562001
Beijing, 100730, China
-
Investigational Site Number : 1562004
Chengdu, 610017, China
-
Investigational Site Number : 1562006
Shenyang, 110004, China
-
Investigational Site Number : 1562008
Jingzhou, 434020, China
-
Investigational Site Number : 1562010
Taiyuan, 030001, China
-
Investigational Site Number : 1562012
Baotou, 014040, China
-
Investigational Site Number : 2032001
Prague, 150 06, Czechia
-
Investigational Site Number : 3481002
Budapest, 1046, Hungary
-
Investigational Site Number : 4101001
Seoul, Seoul-teukbyeolsi, 07061, South Korea
-
Investigational Site Number : 4101003
Seoul, Seoul-teukbyeolsi, 03080, South Korea
-
Investigational Site Number : 8261004
Bradford, BD9 6RJ, United Kingdom
-
Investigational Site Number : 8262002
Wigan, Lancashire, Wn6 9ep, United Kingdom
-
Velocity Clinical Research - San Diego- Site Number : 8402041
La Mesa, California, 91942, United States